Testing a new remote program for people with opioid use disorder
Pilot Testing a Novel Remotely Delivered Intensive Outpatient Program for Individuals With Opioid Use Disorder Hospitalized With Serious Injection-related Infection
This study is testing a new remote program to help people with opioid use disorder who have been hospitalized for serious infections, to see if it can support their recovery after they leave the hospital.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05817825 on ClinicalTrials.gov |
What this trial studies
This pilot trial evaluates a remotely delivered intensive outpatient program (SmartIOP) for individuals hospitalized due to serious injection-related infections associated with opioid use disorder (OUD). The study involves 20 participants who will receive the SmartIOP intervention alongside support from a peer recovery coach. The primary focus is to assess the feasibility of the program and its impact on OUD-related outcomes within 28 days post-discharge. The trial is conducted at Brigham and Women's Hospital, a prominent academic medical center in Boston.
Who should consider this trial
Good fit: Ideal candidates include English-speaking adults aged 18 and older with any DSM-5 substance use disorder who can identify support contacts post-discharge.
Not a fit: Patients with psychotic disorders, active suicidality, or those unable to provide consent due to impaired mental status may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could provide a novel approach to support recovery from opioid use disorder for patients transitioning from hospital to home.
How similar studies have performed: While this approach is innovative, similar interventions have shown promise in improving outcomes for individuals with substance use disorders, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * English-speaking adults aged 18 and above * Any DSM-5 substance use disorder * Can identify at least 2 individuals who can act as points of contact following discharge from the hospital Exclusion Criteria: * Psychotic disorder, active suicidality, or homicidally * Condition likely to be terminal during the study period * Unable to perform consent due to impaired mental status
Where this trial is running
Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Joji Suzuki, MD
- Email: jsuzuki2@bwh.harvard.edu
- Phone: 617-732-5752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.